open access

Vol 52, No 3 (2021)
Clinical vignette
Submitted: 2021-01-22
Accepted: 2021-02-25
Published online: 2021-04-28
Get Citation

A dream that came true: Poland’s first successful CAR-T cell therapy in child with refractory B-cell acute lymphoblastic leukemia (ALL)

Paweł Marschollek1, Karolina Liszka1, Ewa Gorczyńska1, Monika Mielcarek-Siedziuk1, Blanka Rybka1, Joanna Taha2, Krzysztof Kałwak1
DOI: 10.5603/AHP.a2021.0028
·
Acta Haematol Pol 2021;52(3):211-213.
Affiliations
  1. Department of Paediatric Bone Marrow Transplantation, Oncology, and Haematology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland
  2. Department of Paediatrics, Haematology, Oncology and Diabetology, Medical University of Lodz, Kościuszki 4, 90-419 Lodz, Poland

open access

Vol 52, No 3 (2021)
CLINICAL VIGNETTE
Submitted: 2021-01-22
Accepted: 2021-02-25
Published online: 2021-04-28

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

CAR-T cell therapy, acute lymphoblastic leukemia

About this article
Title

A dream that came true: Poland’s first successful CAR-T cell therapy in child with refractory B-cell acute lymphoblastic leukemia (ALL)

Journal

Acta Haematologica Polonica

Issue

Vol 52, No 3 (2021)

Article type

Clinical vignette

Pages

211-213

Published online

2021-04-28

Page views

310

Article views/downloads

195

DOI

10.5603/AHP.a2021.0028

Bibliographic record

Acta Haematol Pol 2021;52(3):211-213.

Keywords

CAR-T cell therapy
acute lymphoblastic leukemia

Authors

Paweł Marschollek
Karolina Liszka
Ewa Gorczyńska
Monika Mielcarek-Siedziuk
Blanka Rybka
Joanna Taha
Krzysztof Kałwak

References (8)
  1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018; 378(5): 439–448.
  2. Cope S, Ayers D, Zhang J, et al. Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia. BMC Med Res Methodol. 2019; 19(1): 182.
  3. Diorio C, Maude SL. CAR T cells vs allogeneic HSCT for poor-risk ALL. Hematology Am Soc Hematol Educ Program. 2020; 2020(1): 501–507.
  4. Styczyński J. Where dreams come true: CAR-T cell therapy in Poland! Acta Haematologica Polonica. 2020; 51(1): 1.
  5. Dytfeld D, Łojko-Dankowska A, Matuszak M, et al. Road to clinical implementation of CAR-T technology in Poznań. Acta Haematologica Polonica. 2020; 51(1): 24–28.
  6. Styczyński J. A brief history of CAR-T cells: from laboratory to the bedside. Acta Haematologica Polonica. 2020; 51(1): 2–5.
  7. Gil L, Łojko-Dankowska A, Matuszak M, et al. CAR-T cell therapy — toxicity and its management. Acta Haematologica Polonica. 2020; 51(1): 6–10.
  8. Styczyński J. Infections following CAR-T cells therapy: current state-of-the-art review and recommendations. Acta Haematologica Polonica. 2020; 51(1): 11–16.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl